Adagrasib

阿达格拉西布

Report date: 2026/05/16 20:00:17
NME

Base Information

Drug NameAdagrasib
Drug Alias Name阿达格拉西KRAZATIMRTX-849
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionKRAS G12C inhibitors
TargetsKRAS G12C
Therapy Area/IndicationsSolid tumoursNeoplasm MetastasisCarcinoma, Non-Small-Cell Lung +[8] 
Global Approved IndicationsCarcinoma, Non-Small-Cell Lung
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2022/12/12
Country/TerritoryCzechiaBelgiumBulgaria +[52] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesMirati Therapeutics IncArray Biopharma
China Registration ClassN/A

Develop Information

Active CompaniesBristol-Myers Squibb (China) Investment Co LtdMirati Therapeutics IncZai Lab (Shanghai) Co Ltd +[7] 
Inactive CompaniesThe University Of Texas MD Anderson Cancer Center
Active IndicationsSolid tumoursNeoplasm MetastasisCarcinoma, Non-Small-Cell Lung +[6] 
Inactive IndicationsColonic NeoplasmsNeoplasms

Other Information

ATC CodeL01XX77
Related LinksWikipediaDrugBankKEGG